Ironwood Pharmaceuticals reported net income of $151.9 million for the nine months ended September 30, 2026. It initiated the 24-week STARS-2 Phase III trial in June 2026 and plans a regulatory filing in 2029.
IRWD · Ironwood Pharmaceuticals Inc
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Price & Indicators
Up next
Latest documents
Ironwood Pharmaceuticals raised its 2026 Linzess net sales guidance to $1.20 to $1.25 billion, representing growth of more than 35% year-over-year, and reported record adjusted EBITDA of $98 million.
Ironwood Pharmaceuticals raised 2026 LINZESS U.S. net sales guidance to $1.20 - $1.25 billion, total revenue to $485 - $510 million and adjusted EBITDA to greater than $350 million. Third-quarter revenue was $133.0 million and adjusted EBITDA was $97.9 million.
On October 12, 2026, Ironwood Pharmaceuticals appointed Chief Commercial Officer Tammi Gaskins as CEO effective January 1, 2027, succeeding Tom McCourt, who retires after 17 years and will remain a director.
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q3 FY26 earnings call · Nov 5, 2026TL;DR. Ironwood raised 2026 guidance as LINZESS prescription demand remained strong, commercial margin improved, and Q3 revenue, net income, and adjusted EBITDA were $133 million, $60 million, and a record $98 million, respectively. The company generated $130.8 million from operations and advanced the STARS-2 trial; key risks include unfavorable net pricing, trial and regulatory uncertainty, reimbursement pressure, and competition.
- + Full-year 2026 LINZESS net sales guidance was raised to $1.20-$1.25 billion, total revenue guidance to $485-$510 million, and adjusted EBITDA guidance to greater than $350 million.
- + Q3 2026 total revenue was $133 million, GAAP net income was $60 million, and adjusted EBITDA was a record $98 million.
- + LINZESS Q3 2026 prescription demand increased 4.9%.
- + LINZESS commercial margin improved to 79.8% in Q3 2026 from 75.9% in Q3 2025.
- + Ironwood generated $130.8 million from operations in Q3 2026.
- + The STARS-2 trial's planned activation of more than 100 sites across 22 countries is on track.
- − LINZESS Q3 2026 net sales growth was constrained by a low single-digit net price decline caused by unfavorable gross-to-net rebate reserves.
- − Apraglutide's planned 2029 regulatory filing is contingent on the results of the confirmatory STARS-2 trial.
- − Apraglutide may not receive regulatory approval from the FDA or other regulatory agencies.
- − Clinical programs may be delayed or discontinued because of safety, tolerability, enrollment, manufacturing, economic, or other reasons.
- − Unfavorable pricing and reimbursement policies could hinder or prevent LINZESS's commercial success.
- − Apraglutide faces competition from new products that may provide different or better treatment alternatives.
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Mentioned in fund letters
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Guidance & track record
Still-open targets the latest release did not restate under the same label.
Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Adjusted EBITDA non-GAAP | $83M | Q2 2026 | — |
| Adjusted EBITDA guidance non-GAAP | $310M | Updated 2026 Guidance (August 2026) | — |
| LINZESS commercial margin | 78% | Q2 2026 | — |
| LINZESS U.S. brand collaboration net profit | $214.6M | Q2 2026 | — |
| LINZESS U.S. collaboration revenue to Ironwood | $110M | Q2 2026 | — |
| LINZESS U.S. net sales | $282.3M | Q2 2026 | — |
| Total LINZESS demand | 59.8M | Q2 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Drug Manufacturers - Specialty & Generic — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
IRWD
this stock
Ironwood Pharmaceuticals Inc
|
$767.33M | +41.8% | +8.9% | 5.2 | 9.0% |
|
TAK
Takeda Pharmaceutical Co Ltd
|
$67.96B | +36.4% | — | — | 0.1% |
|
GALDY
Galderma Group AG
|
$51.90B | +7.4% | — | — | 0.0% |
|
TEVA
Teva Pharmaceutical Industries Ltd
|
$49.28B | +35.3% | +4.3% | 96.0 | 2.4% |
|
JHPCY
Jiangsu Hengrui Pharmaceuticals Co., Ltd.
|
$40.66B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every section- Filed
- Nov 5, 2026
- This year
- 21
Ironwood Pharmaceuticals reported net income of $151.9 million for the nine months ended September 30, 2026. It initiated the 24-week STARS-2 Phase III trial in June 2026 and plans a regulatory filing in 2029.
ViewPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| IRWD | -1.9% | +34.7% | +33.9% | +36.6% | +41.8% |
| SPY | -3.9% | -5.6% | -3.5% | -3.4% | +7.1% |
| vs SPY | +2.1% | +40.2% | +37.4% | +40.0% | +34.8% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.